Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Klaria Pharma Holding AB currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being examined within 1 distinct art unit, indicating a specific focus for the company's current patent activity. The prosecution involves 1 distinct examiner, which simplifies the communication process for this active case by providing a point of contact at the patent office.
The busiest examiner is HOLLOMAN, NANNETTE, who is responsible for the 1 busiest examiner pending action. Since there is only 1 pending office action, this examiner holds the active workload. This alignment between pending actions and examiners ensures that the prosecution strategy remains focused on a set of examiner requirements without the need to coordinate across different departments.
Navigating a portfolio with only 1 pending office action allows for a concentrated effort on the specific technical requirements of the 1 distinct art unit involved. Practitioners can dedicate their resources to addressing the feedback from HOLLOMAN, NANNETTE, ensuring that the active matter in the Biotechnology & Pharmaceuticals sector receives attention during the examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19088128 | Pharmaceutical Formulation | HOLLOMAN, NANNETTE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19088128 | Pharmaceutical Formulation | HOLLOMAN, NANNETTE | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Mar 24, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKlaria Pharma Holding AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nannette Holloman has the most, with 1 of Klaria Pharma Holding AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.